Joan Merrill to Immunosuppressive Agents
This is a "connection" page, showing publications Joan Merrill has written about Immunosuppressive Agents.
Connection Strength
4.141
-
New Trials in Lupus and where Are we Going. Curr Rheumatol Rep. 2018 05 03; 20(6):34.
Score: 0.563
-
The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials. Arthritis Rheumatol. 2017 06; 69(6):1257-1266.
Score: 0.528
-
Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol. 2014 Feb; 66(2):379-89.
Score: 0.419
-
Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum. 2012 Oct; 64(10):3364-73.
Score: 0.382
-
Treatment of systemic lupus erythematosus: a 2012 update. Bull NYU Hosp Jt Dis. 2012; 70(3):172-6.
Score: 0.363
-
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon a monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011 Nov; 70(11):1905-13.
Score: 0.352
-
Ending the 50-year drought of FDA drug approval for SLE. Bull NYU Hosp Jt Dis. 2011; 69(3):238-42.
Score: 0.339
-
Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. Arthritis Care Res (Hoboken). 2020 12; 72(12):1800-1808.
Score: 0.168
-
Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. Nat Rev Rheumatol. 2020 10; 16(10):581-589.
Score: 0.164
-
Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 07; 71(7):1125-1134.
Score: 0.152
-
Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index. Rheumatology (Oxford). 2018 01 01; 57(1):125-133.
Score: 0.138
-
Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study. Arthritis Care Res (Hoboken). 2016 Apr; 68(4):534-43.
Score: 0.122
-
Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol. 2014 Feb; 41(2):300-9.
Score: 0.103
-
The genetics of systemic lupus erythematosus and implications for targeted therapy. Ann Rheum Dis. 2011 Mar; 70 Suppl 1:i37-43.
Score: 0.086
-
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005 Nov 24; 353(21):2219-28.
Score: 0.059
-
Prediction of Hospitalizations in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. Arthritis Care Res (Hoboken). 2022 04; 74(4):638-647.
Score: 0.046
-
Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. Arthritis Care Res (Hoboken). 2021 12; 73(12):1789-1795.
Score: 0.045
-
Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. Arthritis Rheumatol. 2020 04; 72(4):658-666.
Score: 0.040
-
Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. Arthritis Care Res (Hoboken). 2019 07; 71(7):893-902.
Score: 0.038
-
Brief Report: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis. Arthritis Rheumatol. 2018 07; 70(7):1071-1076.
Score: 0.035